Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-CD123 CAR NK cells · 1 trial · 2 indications
The incidence of adverse events after CAR-NK cell infusion was assessed by CTCAE, version 5.0.
| Arm | Type | Description |
|---|---|---|
| CD123 CAR-NK cells | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Anti-CD123 CAR NK cells | DRUG | Each patient will receive two CAR-NK cell infusions at D0 and D7, and CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion. |
Inclusion Criteria: 1. Patients of any gender, aged between 18 and 75 years (inclusive); 2. Positive expression of CD123 on tumor cells detected by flow cytometry; 3. Patients with a confirmed diagnosis of CD123-positive relapsed/refractory AML or BPDCN: (1) For AML patients： * Relapsed refers to...
Anti-CD123 CAR NK cells is an investigational cell therapy being studied for the treatment of acute myeloid leukemia (AML). It is also being evaluated for blastic plasmacytoid dendritic cell neoplasm (BPDCN). The therapy is currently in Phase 1 clinical development.
Anti-CD123 CAR NK cells targets CD123, a protein expressed on leukemic cells. The therapy uses natural killer (NK) cells engineered with a chimeric antigen receptor (CAR) to recognize and attack CD123-positive cells, which may help treat AML and BPDCN.
Anti-CD123 CAR NK cells is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol DTIL. The company is conducting a Phase 1 clinical trial for this investigational therapy.
Anti-CD123 CAR NK cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate the therapy's safety and efficacy.
Anti-CD123 CAR NK cells is being studied in a Phase 1 clinical trial with the identifier NCT06690827. This trial is recruiting 30 participants with relapsed or refractory AML or BPDCN in China. The study is open to adults aged 18 years and older.
Yes, Anti-CD123 CAR NK cells is also referred to as CD123-targeted CAR-NK therapy. The clinical trial NCT06690827 is titled 'Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN,' confirming the same investigational therapy.